Study characteristics of studies informing NC19CET recommendation for remdesivir *

Study characteristic	Biegel 2020 Remdesivir	Standard care	Wang 2020 Remdesivir	Standard care	Spinner 2020 Remdesivir 5-day	Remdesivir 10-day	Standard care	Goldman 2020 Remdesivir 5-day	Remdesivir 10-day	SOLIDARITY 2020 Remdesivir	Standard care
No. of patients (N)	541	521	158	78	191	193	200	200	197	2743	2708
Age (years)	58.6 (SD 14.6)	59.2 (SD 15.4)	66 (range 57-73)	64 (range 53-70)	58 (IQR 48-66)	56 (IQR 45-66)	57 (IQR 45-66)	61 (IQR 50-69)	62 (IQR 50-71)		
Gender (female; %)	34.9	36.3	44	35	40	39	38	40	32	38	36
Pregnant patients	Excluded		Excluded		Excluded			Excluded		Excluded	
Paediatric patients	Excluded		Excluded		> 12 years (if over 40 kg)			Excluded		Excluded	
Primary exclusion criteria	ALT or AST > 5 x ULN; eGFR < 30 mL/min per 1.73 m^2; allergy to study medication		Hepatic cirrhosis; ALT or AST > 5 x ULN; eGFR < 30 mL/min per 1.73 m^2; enrolment in an investigational study for COVID-19 within 30 days before commencement		Treatment with other antiviral agent 24 hours before study commencement; requiring mechanical ventilation; ALT or AST > 5 x ULN, creatinine clearance < 50 mL/min			Treatment with other antiviral agent 24 hours before study commencement; multiorgan failure; requiring mechanical ventilation; ALT or AST > 5 x ULN, creatinine clearance < 50 mL/min		Anticipated transfer within 72 hours, to non-study site Death likely within 24 hours Allergy to study medication Receiving one of the study drugs	
Dose and duration											
Dose (loading)	200mg q.d.	-	200mg q.d.	-	200mg q.d.	200mg q.d.	-	200mg q.d.	200mg q.d.	200mg q.d.	
Dose (maintenance)	100 mg q.d.	-	100 mg q.d.	-	100 mg q.d.	100 mg q.d.	-	100 mg q.d.	100 mg q.d.	100mg q.d.	
Scheduled duration (days)	10 days	-	10 days	-	5 days	10 days	-	5 days	10 days	10 days	
Actual duration (median)	NR	-	NR	-	5 days	6 days	-	5 days	9 days	NR	
Route of administration	IV	-	IV	-	IV	IV	-	IV	IV	IV	
Disease severity											
- Mild (%)	0	0	0	0	0	3	1	0	0		
- Moderate (%)	53.4	49.6	82	87	99	96	98	73	65		
- Severe (%)	18.1	19.0	18	12	1	1	1	24	30		
- Critical (%)	23.1	28.2	0	1	0	0	0	2	5	9	9
- No oxygen (%)	13.9	12.1	0	4	84	87	81	17	11	24	25
- Oxygen (%)	42.9	39	82	83	15	12	18	56	54	67	67
- Ventilated (%)	41.8	48.4	18	13	1	1	1	26	35	9	9
Co-administered interventions											

- Hydroxychloroquine (%)	NR	NR	NR	NR	8	11	45	NR	NR	NR	NR
- Lopinavor-ritonavir (%)	NR	NR	28	29	5	6	22	NR	NR	NR	NR
- Corticosteroids (%)	NR	NR	65	68	17	15	19	NR	NR	NR	NR
- Tocilizumab (%)	NR	NR	NR	NR	1	1	5	NR	NR	NR	NR
- Azithromycin (%)	NR	NR	NR	NR	18	21	31	NR	NR	NR	NR
Comorbidities											
- Cardiovascular disease (%)	NR	NR	9	3	58	58	54	NR	NR	21	21
- Hypertension (%)	50.6	50.9	46	38	43	44	41	50	50	NR	NR
- Diabetes (%)	30.8	30.4	25	21	37	44	38	24	22	26	25
- Obesity (%)	45.6	45.2	NR	NR	NR	NR	NR	NR	NR	NR	NR
- Asthma (%)	NR	NR	NR	NR	12	16	14	14	11	5	5